GEHC Stock Analysis
NMS · Healthcare · Medical Devices
$66.63
+0.25 (+0.38%)
GEHC Interactive Price Chart & Trading Signals
GEHC Stock Snapshot — Valuation, Risk & Technical Signals
GEHC Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$30.10B
P/E Ratio
15.35
Forward P/E
12.31
PEG Ratio
1.66
P/B Ratio
2.74
EPS
$4.34
Dividend Yield
0.24%
52W Range
$58.75 – $89.77
Beta
0.82
Volume
4.2M
ROE
19.4%
Profit Margin
9.3%
Revenue Growth
5.8%
Gross Margin
39.5%
EV/EBITDA
10.80
Analyst Target
$83.05
The trailing price-to-earnings ratio stands at 15.4x. Forward P/E of 12.3x implies earnings expansion expected. Price-to-book is 2.74x. EV/EBITDA sits at 10.80x. Market capitalization is $30.10B. Revenue is growing at 5.8% on a trailing basis. Earnings are expanding at 16.8%. Profit margins are 9.3%. Return on equity is 19.4%. Beta of 0.82 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$70.00
Mean Target
$83.05
High Target
$96.00
Based on 19 analysts
About GEHC
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
GEHC Deep Dive Analysis
Bottom Line
Verdict
Fairly ValuedBest for
General investorWatch out for
None flaggedNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
GE HealthCare Technologies Inc. (GEHC) trades near our multi-model fair value estimate of $59.26 by approximately 11.1%. Trailing P/E: 15.4x. Profitability signals include profit margin of 9.3% and return on equity of 19.4%. Recent growth metrics show revenue growth of 5.8% and earnings growth of 16.8%. Risk profile: beta of 0.82. Consensus: buy.
Valuation, Growth & Risk
Valuation
Fairly Valued
P/E 15.4x
Price is close to fair value estimate.
Growth
Expanding
Rev 5.8%
Revenue is outpacing the market.
Valuation Snapshot
GE HealthCare Technologies Inc. (GEHC) trades near our multi-model fair value estimate of $59.26 by approximately 11.1%. The trailing price-to-earnings ratio stands at 15.4x. Forward P/E of 12.3x suggests earnings compression ahead. Price-to-sales is 1.4x. Price-to-book is 2.7x. EV/EBITDA sits at 10.8x. Market capitalization is $30.10B.
Why it matters: A fairly valued stock means you are paying roughly what the business is worth today.
Growth & Profitability
Revenue is growing at 5.8% on a trailing basis. Earnings are expanding at 16.8%. Profit margins are 9.3%. Return on equity is 19.4%. Return on assets is 5.1%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.82 indicates market-average volatility. Net debt position is $8.46B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $83.05 implies 24.6% upside. Target range spans $70.00 to $96.00. 19 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Free cash flow yield of 5.0% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
GEHC Fairly Valued
GE HealthCare Technologies Inc. (GEHC) trades near our multi-model fair value estimate of $59.26 by approximately 11.1%.
Frequently Asked Questions
ValuationIs GEHC stock overvalued right now?
ValuationWhat is GEHC fair value based on current fundamentals?
RiskHow risky is GEHC compared with other stocks?
GrowthIs GEHC still growing?
AnalystWhat do analysts think about GEHC?
DividendDoes GEHC pay a dividend?
CatalystWhat could change the investment case for GEHC?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.